| Year |
Citation |
Score |
| 2023 |
Marino S, Petrusca DN, Bishop RT, Anderson JL, Sabol HM, Ashby C, Layer JH, Cesarano A, Davé UP, Perna F, Delgado-Calle J, Chirgwin JM, Roodman GD. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma. Haematologica. PMID 37981834 DOI: 10.3324/haematol.2023.283787 |
0.321 |
|
| 2019 |
Marino S, Petrusca DN, Simpson E, Anderson JL, Xie X, Liu Y, Chirgwin J, Roodman GD. Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors Blood. 134: 4391-4391. DOI: 10.1182/Blood-2019-131865 |
0.305 |
|
| 2018 |
Zhou D, Bum-Erdene K, Xu D, Liu D, Tompkins D, Sulaiman RS, Corson TW, Chirgwin JM, Meroueh SO. Small molecules inhibit ex vivo tumor growth in bone. Bioorganic & Medicinal Chemistry. PMID 30470597 DOI: 10.1016/J.Bmc.2018.11.025 |
0.468 |
|
| 2018 |
Lontos K, Adamik J, Tsagianni A, Galson DL, Chirgwin JM, Suvannasankha A. The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis. Frontiers in Endocrinology. 9: 322. PMID 29971044 DOI: 10.3389/Fendo.2018.00322 |
0.446 |
|
| 2018 |
Suvannasankha A, Crean C, Ochoa IC, Roodman GD, Chirgwin J. PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease Blood. 132: 4450-4450. DOI: 10.1182/Blood-2018-99-115680 |
0.473 |
|
| 2017 |
Juárez P, Fournier PGJ, Mohammad KS, McKenna RC, Davis HW, Peng XH, Niewolna M, Mauviel A, Chirgwin JM, Guise TA. Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis. Oncotarget. 8: 86447-86462. PMID 29156807 DOI: 10.18632/oncotarget.21200 |
0.383 |
|
| 2016 |
Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD, Bellido T. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma. Cancer Research. 76: 1089-100. PMID 26833121 DOI: 10.1158/0008-5472.CAN-15-1703 |
0.414 |
|
| 2016 |
Suvannasankha A, Crean CD, Tompkins DR, Delgado-Calle J, Bellido TM, Roodman GD, Chirgwin JM. Regulation of Osteoblast Function in Myeloma Bone Disease By Semaphorin 4D Blood. 128: 4439-4439. DOI: 10.1182/Blood.V128.22.4439.4439 |
0.451 |
|
| 2015 |
Fournier PG, Juárez P, Jiang G, Clines GA, Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, Wells CD, Chirgwin JM, Guise TA. The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. Cancer Cell. 27: 809-21. PMID 25982816 DOI: 10.1016/J.Ccell.2015.04.009 |
0.349 |
|
| 2015 |
Suvannasankha A, Tompkins DR, Edwards DF, Petyaykina KV, Crean CD, Fournier PG, Parker JM, Sandusky GE, Ichikawa S, Imel EA, Chirgwin JM. FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget. PMID 25944690 |
0.369 |
|
| 2014 |
Suvannasankha A, Chirgwin JM. Role of bone-anabolic agents in the treatment of breast cancer bone metastases. Breast Cancer Research : Bcr. 16: 484. PMID 25757219 DOI: 10.1186/s13058-014-0484-9 |
0.519 |
|
| 2014 |
Siclari VA, Mohammad KS, Tompkins DR, Davis H, McKenna CR, Peng X, Wessner LL, Niewolna M, Guise TA, Suvannasankha A, Chirgwin JM. Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis. Breast Cancer Research : Bcr. 16: 458. PMID 25439669 DOI: 10.1186/S13058-014-0458-Y |
0.61 |
|
| 2013 |
Suvannasankha A, Tompkins DR, Petyaykina K, Crean CD, Condon KW, David Roodman GD, Chirgwin JM. Neonatal Mouse Bone Supports Growth Of Primary Myeloma Cells Ex Vivo and Assessment Of Responses To Antimyeloma Drugs Blood. 122: 1893-1893. DOI: 10.1182/blood.v122.21.1893.1893 |
0.358 |
|
| 2012 |
Juárez P, Mohammad KS, Yin JJ, Fournier PG, McKenna RC, Davis HW, Peng XH, Niewolna M, Javelaud D, Chirgwin JM, Mauviel A, Guise TA. Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Research. 72: 6247-56. PMID 23002206 DOI: 10.1158/0008-5472.CAN-12-1444 |
0.335 |
|
| 2012 |
Chirgwin JM. The stem cell niche as a pharmaceutical target for prevention of skeletal metastases. Anti-Cancer Agents in Medicinal Chemistry. 12: 187-93. PMID 22044002 |
0.392 |
|
| 2011 |
Clines GA, Mohammad KS, Grunda JM, Clines KL, Niewolna M, McKenna CR, McKibbin CR, Yanagisawa M, Suva LJ, Chirgwin JM, Guise TA. Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 26: 2523-36. PMID 21698666 DOI: 10.1002/jbmr.450 |
0.3 |
|
| 2011 |
Fournier P, Edwards D, White K, Chirgwin* J. Osteocyte-derived FGF23 activates EGR-1 signaling in prostate cancer cells: A new vicious cycle in bone metastases Bone. 48: S48. DOI: 10.1016/j.bone.2010.10.136 |
0.333 |
|
| 2010 |
Chirgwin JM, Edwards CM, Pedersen EA, Shiozawa Y, Taichman RS, Park SI, McCauley LK, Matsumoto T, Abe M. Meeting report from the IX international meeting on cancer induced bone disease Ibms Bonekey. 7: 32-46. DOI: 10.1138/20100426 |
0.388 |
|
| 2009 |
Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. Plos One. 4: e6896. PMID 19727403 DOI: 10.1371/Journal.Pone.0006896 |
0.453 |
|
| 2009 |
Mohammad KS, Fournier PG, Guise TA, Chirgwin JM. Agents targeting prostate cancer bone metastasis. Anti-Cancer Agents in Medicinal Chemistry. 9: 1079-88. PMID 19719455 DOI: 10.2174/187152009789735008 |
0.407 |
|
| 2009 |
Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Molecular and Cellular Endocrinology. 310: 71-81. PMID 19616059 DOI: 10.1016/J.Mce.2009.07.004 |
0.536 |
|
| 2008 |
Mohammad KS, Chirgwin JM, Guise TA. Assessing new bone formation in neonatal calvarial organ cultures. Methods in Molecular Biology (Clifton, N.J.). 455: 37-50. PMID 18463809 DOI: 10.1007/978-1-59745-104-8_3 |
0.335 |
|
| 2008 |
Fournier P, Clines G, Chirgwin J, Guise T. P32. Transforming growth factor-β (TGF-β) promotes prostate cancer bone metastases: Increased expression of pro-osteolytic genes and of PMEPA1, a new TGF-β signalling regulator Cancer Treatment Reviews. 34: 25. DOI: 10.1016/J.Ctrv.2008.03.074 |
0.323 |
|
| 2008 |
Kingsley L, Fournier P, Chirgwin J, Guise T. P16. Hypoxia and breast cancer bone metastasis: HIF-1α enhances TGF-β signaling and expression of prometastatic factors CXCR4 and VEGF Cancer Treatment Reviews. 34: 18. DOI: 10.1016/J.Ctrv.2008.03.058 |
0.407 |
|
| 2007 |
Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Molecular Cancer Therapeutics. 6: 2609-17. PMID 17938257 DOI: 10.1158/1535-7163.MCT-07-0234 |
0.44 |
|
| 2007 |
Chirgwin JM, Guise TA. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. Journal of Cellular Biochemistry. 102: 1333-42. PMID 17907152 DOI: 10.1002/jcb.21556 |
0.433 |
|
| 2007 |
Kingsley LA, Chirgwin JM, Guise TA. Breaking new ground to build bone. Proceedings of the National Academy of Sciences of the United States of America. 104: 10753-4. PMID 17581868 DOI: 10.1073/pnas.0704357104 |
0.318 |
|
| 2007 |
Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD, Fox JW, Chirgwin JM, Guise TA. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Molecular Endocrinology (Baltimore, Md.). 21: 486-98. PMID 17068196 DOI: 10.1210/me.2006-0346 |
0.335 |
|
| 2007 |
Bartholin L, Wessner LL, Chirgwin JM, Guise TA. The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Letters. 246: 230-6. PMID 16616811 DOI: 10.1016/j.canlet.2006.02.019 |
0.47 |
|
| 2006 |
Siclari VA, Guise TA, Chirgwin JM. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Reviews. 25: 621-33. PMID 17165131 DOI: 10.1007/S10555-006-9023-1 |
0.611 |
|
| 2006 |
Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6213s-6216s. PMID 17062703 DOI: 10.1158/1078-0432.Ccr-06-1007 |
0.415 |
|
| 2006 |
Fournier PG, Chirgwin JM, Guise TA. New insights into the role of T cells in the vicious cycle of bone metastases. Current Opinion in Rheumatology. 18: 396-404. PMID 16763461 DOI: 10.1097/01.bor.0000231909.35043.da |
0.444 |
|
| 2006 |
Zudaire E, Martínez A, Garayoa M, Pío R, Kaur G, Woolhiser MR, Metcalfe DD, Hook WA, Siraganian RP, Guise TA, Chirgwin JM, Cuttitta F. Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. The American Journal of Pathology. 168: 280-91. PMID 16400030 DOI: 10.2353/ajpath.2006.050291 |
0.304 |
|
| 2005 |
Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Suva LJ. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Research. 65: 11001-9. PMID 16322249 DOI: 10.1158/0008-5472.Can-05-2630 |
0.337 |
|
| 2005 |
Titus B, Frierson HF, Conaway M, Ching K, Guise T, Chirgwin J, Hampton G, Theodorescu D. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Research. 65: 7320-7. PMID 16103083 DOI: 10.1158/0008-5472.Can-05-1403 |
0.334 |
|
| 2005 |
Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM. Molecular mechanisms of breast cancer metastases to bone. Clinical Breast Cancer. 5: S46-53. PMID 15807924 |
0.503 |
|
| 2003 |
Guise TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clinical Orthopaedics and Related Research. S32-8. PMID 14600590 DOI: 10.1097/01.blo.0000093055.96273.69 |
0.487 |
|
| 2003 |
Guise TA, Chirgwin JM. Role of bisphosphonates in prostate cancer bone metastases. Seminars in Oncology. 30: 717-23. PMID 14571419 |
0.346 |
|
| 2003 |
Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proceedings of the National Academy of Sciences of the United States of America. 100: 10954-9. PMID 12941866 DOI: 10.1073/Pnas.1830978100 |
0.5 |
|
| 2003 |
Chirgwin JM, Guise TA. Molecular mechanisms of cancer metastases to bone Current Opinion in Orthopaedics. 14: 317-321. DOI: 10.1097/00001433-200310000-00003 |
0.414 |
|
| 2000 |
Chirgwin JM, Guise TA. Molecular Mechanisms of Tumor-Bone Interactions in Osteolytic Metastases Critical Reviews in Eukaryotic Gene Expression. 10: 20. DOI: 10.1615/CRITREVEUKARGENEEXPR.V10.I2.50 |
0.34 |
|
| 1999 |
Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise TA. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. The Journal of Clinical Investigation. 103: 197-206. PMID 9916131 DOI: 10.1172/Jci3523 |
0.4 |
|
| Show low-probability matches. |